Navigation Links
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
Date:4/21/2009

- Preclinical Studies Highlight the Ability of PS-Targeting Antibodies to Reverse the Immune Suppressing Effects of Tumors by Changing the Tumor Microenvironment and Mobilizing Key Components of the Immune System -

- Studies Confirm Peregrine's PS-Targeting Antibodies Stimulate Dendritic Cell Maturation, Inflammatory Cytokine and Chemokine Release and Recruitment of Macrophages to Tumors -

DENVER and TUSTIN, Calif., April 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS)-targeting antibodies. One study confirms the anti-tumor effects and immune stimulating ability of a fully human anti-PS antibody and the other demonstrates the ability of a second fully human anti-PS antibody to stimulate development of a critical component of the adaptive immune system.

These human PS-targeting antibodies, which are currently being evaluated for both anti-cancer and anti-viral applications, increase the number of product candidates in Peregrine's anti-PS pipeline. Peregrine's lead anti-PS antibody bavituximab is currently in Phase II clinical trials in advanced breast and lung cancers.

"These preclinical studies further elucidate the unique immunomodulatory mechanisms contributing to the observed anti-tumor activity of anti-PS antibodies in preclinical and clinical studies," said Dr. Philip Thorpe, professor of pharmacology at UT Southwestern Medical Center in Dallas, a scientific advisor to Peregrine and co-author of one
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
2. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
3. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
4. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
5. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
6. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
7. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
8. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
9. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
10. Oridion Announces Significant Medical Studies Presented at STA
11. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)... 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of Directors ... who will serve on Medimetriks, Audit Committee, brings ... the Company.  Mr. Lary is currently Managing Director, ... institutional investment firm.  Mr. Lary is responsible for ...
(Date:9/23/2014)... 23, 2014  Vesselon, Inc. today announced the appointment ... effective September 15, 2014. Dr. Raths, appointment follows Vesselon,s ... agent to market a private preferred Series A round ... treatment. "Jurgen,s deep experience across multiple functional ... asset to Vesselon as we develop our device that ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- Few children ... undergo behavioral therapy, and the rates vary six-fold ... study finds. Medication alone can manage symptoms ... better if they also receive behavioral therapy (psychotherapy), ... analyzed data in more than 1,500 counties across ...
(Date:9/23/2014)... grow up to earn up to 18 percent less ... Lundborg of Lund University, Paul Nystedt of Jnkping University ... all in Sweden. The team compared extensive information from ... the results are published in Springer,s journal Demography ... 145,193 Swedish-born brothers who enlisted in the Swedish National ...
(Date:9/23/2014)... 23, 2014 Vancouver Electrician Contractors, Pro ... offering commercial electrical services in Vancouver, BC. The company ... it is a small maintenance project or a large-scale ... package to meet the needs of the individual commercial ... will be of an affordable price. As a result, ...
(Date:9/23/2014)... 2014 The Sloane Clinic™, a ... and Malaysia providing advanced aesthetic dermatology and cosmetic ... its impressive skin care repertoire. Specially formulated with ... against the evil forces of aging, acne and ... this new addition is revolutionizing the way we ...
(Date:9/23/2014)... York (PRWEB) September 23, 2014 Risperdal ... courts around the country, Bernstein Liebhard LLP reports. According ... District of Florida on September 19th, the Court has ... case filed in that jurisdiction on behalf of a ... other complications due to his use of Risperdal. In ...
Breaking Medicine News(10 mins):Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Note to young men: Fat doesn't pay 2Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3
... , CAMBRIDGE, Mass., Sept. 9 ... enterprise content compliance software solutions for ... Software-as-a-Service (SaaS) solution for managing clinical trial disclosure requirements. The ... a robust offering that automates compliance with global regulatory mandates ...
... , NASHVILLE, Tenn., Sept. 9 ... provider of revenue and payment cycle management solutions, today ... Healthcare Network Accreditation Program (HNAP) from the Electronic Healthcare ... in health data processing and transactions and indicates compliance ...
... STOCKHOLM, September 9 Karolinska Development ... that will commercialize its,dermatology and wound healing opportunities as ... all of its,holdings from its five dermatology and wound ... company. , "This is a ...
... New Hearing ... ... website www.AdviceOnHearingAids.com is proving to be a valuable and informative resource for consumers ... aids, and so many different brands, styles, types of technology, and opinions about which one ...
... , TITUSVILLE, N.J., Sept. 9 Attention ... percent of children(1) and 4 percent of adults in the U.S.(2) ... 20 percent of U.S. school-aged children meet the Diagnostic and Statistical ... receiving an ADHD diagnosis.(3) Meanwhile, it is estimated that just 15 ...
... , , , HERMOSA ... empower parents across the globe to participate in the fight against AIDS ... ... go outside, go discover, go experience. Through the new partnership with ... to not only improve their own lives, but also the lives of ...
Cached Medicine News:Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 2Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 3Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 4Health News:Emdeon Receives EHNAC Healthcare Network Re-accreditation 2Health News:Emdeon Receives EHNAC Healthcare Network Re-accreditation 3Health News:Karolinska Development Introduces New Concept for Development of its Dermatology and Wound Healing Portfolio 2Health News:Help for Hearing Loss - Now Available Online 2Health News:Help for Hearing Loss - Now Available Online 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 2Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 4Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 5Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 2Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 3Health News:'Go and Good Things Happen' with (BUGABOO)(RED) 4
... is an inverted system microscope ... imaging needs of high-level laboratory ... and the excellence of its ... cell culture observation to fluorescence ...
... The SZX microscope system is ... the Olympus line. Long working distance, ... and easy operation are matched by ... motorized components giving the SZX great ...
... The MicroFire is a 2-megapixel, 12-bit FireWire digital camera. ... be acquired effortlessly. Imaging has never been this easy! ... CCD - 2/3" Color ... Time - 500 microseconds - 60 seconds ...
... a Progressive Scan 1/2" CCD with square pixels ... (V) SXGA. Whats more the XCD-SX910CR uses a ... "Bayer filter") and outputs the "raw color" pixel ... converted to a color image on the computer. ...
Medicine Products: